Vyne Therapeutics INC

Yarrow Bioscience reported Q3 2026 results, highlighting a substantial capital raise and ongoing Phase 2a/2b trial for YB-101, with topline data expected in late 2027.

Yarrow Bioscience, Inc. has successfully completed a public offering of its common stock, raising approximately $161.8 million in net proceeds.

Yarrow Bioscience, Inc. has made significant updates regarding its lead drug candidate, YB-101, including progress in clinical trials for Graves' Disease and Thyroid Eye Disease, and a corporate presentation detailing its strategy and financial position.

Yarrow Bioscience, Inc. (now Yarrow Bioscience Operating Company Corp.) announced the completion of its merger with VYNE Therapeutics, securing approximately $200 million in financing and providing an estimated cash runway into 2028, while advancing its lead drug candidate YB-101 for autoimmune thyroid diseases.

Yarrow Bioscience, Inc. announced an exchange of common stock for pre-funded warrants, impacting outstanding share counts and ownership limitations.

Yarrow Bioscience, Inc. (formerly VYNE Therapeutics Inc.) announced the closing of its merger with Yarrow Bioscience, Inc. and the commencement of dosing in a Phase 2a/2b trial for YB-101, a potential treatment for Graves' disease and thyroid eye disease.

Yarrow Bioscience reports substantial cash reserves and advancement in its lead drug candidate YB-101 trials, alongside a net loss for the quarter.

Yarrow Bioscience, Inc. (formerly VYNE Therapeutics) reported its Q2 2026 results, highlighting the completion of its merger with Yarrow and a continued focus on its lead candidate YB-101, while managing significant accumulated deficits and future funding needs.

VYNE Therapeutics reported a reduced net loss for Q3 2025, but terminated its Phase 2b repibresib trial for vitiligo and faces a partial clinical hold on VYN202, prompting a strategic review and cost reductions.

VYNE Therapeutics reported mixed clinical trial results for VYN202 and repibresib, leading to trial terminations, while implementing cost reductions to extend its cash runway into the first half of 2027.

VYNE Therapeutics announces its Q1 2025 financial results, including a net loss of $8.6 million, and reports a clinical hold on its Phase 1b trial of VYN202 due to testicular toxicity observed in preclinical studies.

VYNE Therapeutics reported a net loss of $12.16 million for the third quarter of 2024, with increased research and development expenses due to ongoing clinical trials.

VYNE Therapeutics announced a definitive merger agreement with Yarrow Biosciences, shifting its strategic focus to Yarrow's clinical-stage TSHR antibody for Graves Disease, following setbacks in its BET inhibitor programs.

VYNE Therapeutics' 10-K filing summarizes the company's financial performance for 2024 and provides updates on its clinical development programs, including repibresib gel and VYN202.

VYNE Therapeutics Inc. reports its 2023 financial results and provides updates on its clinical-stage immuno-inflammatory drug development programs, including VYN201 and VYN202.

Lori Payton, Chief Development Officer of VYNE Therapeutics Inc., received 99,827 shares of common stock on October 29, 2026.

Rachael Alford, Chief Operating Officer of VYNE Therapeutics Inc., received 89,844 shares of common stock on October 29, 2026.

Rebecca Frey, Chief Executive Officer and a Director of VYNE Therapeutics Inc., received 465,857 shares of common stock on October 29, 2026.

Steven Ryder, Chief Medical Officer of VYNE Therapeutics Inc., received 113,137 shares of common stock on October 29, 2026.

Tyler Zeronda, Chief Financial Officer of VYNE Therapeutics Inc., received 156,115 shares of common stock on October 29, 2026.

RTW Fund Group GP, LLC and 1 other reported changes in beneficial ownership of VYNE Therapeutics Inc. common stock on July 29, 2026.

VYNE Therapeutics Inc. announces its 2025 Annual Meeting of Stockholders to vote on director elections, auditor ratification, and executive compensation, while revealing increasing net losses and a recent Phase 2b trial failure.

VYNE Therapeutics is holding its annual meeting on December 12, 2024, to vote on key proposals including the election of directors, ratification of the auditor, executive compensation, and an amendment to the equity incentive plan.

OrbiMed Advisors LLC and affiliated entities have filed a Schedule 13D, disclosing beneficial ownership of approximately 9.97% of Yarrow Bioscience, Inc. common stock following a merger.

AI Biotechnology LLC and affiliated entities report a 6.02% stake in Yarrow Bioscience, Inc. following a merger and stock split.

Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, has filed a Schedule 13G, disclosing beneficial ownership of 39,198 shares of Yarrow Bioscience, Inc. common stock, representing 0.46% of the class.

Spruce Street Capital LP, along with its co-managing members Alex R. Rosen and Simon Basseyn, has reported beneficial ownership of 607,382 shares, representing 6.4% of Yarrow Bioscience, Inc.'s common stock.

Bellevue Group AG and its subsidiary Bellevue Asset Management AG have reported beneficial ownership of 10.6% of Yarrow Bioscience, Inc. common stock.

Several entities affiliated with Invus Group and Raymond Debbane have reported beneficial ownership of 7.2% of Yarrow Bioscience, Inc. common stock as of September 17, 2026.

ADAR1 Capital Management, LLC and Daniel Schneeberger have jointly filed a Schedule 13G, reporting beneficial ownership of 8.8% of Yarrow Bioscience, Inc. common stock as of June 30, 2026.

Zhang Xiaofan has filed a Schedule 13G, reporting beneficial ownership of 0.6% of Yarrow Bioscience, Inc. common stock.